De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China

Abstract Background: Long‐term treatment‐free remission (TFR) represents a new goal for chronic myeloid leukemia (CML). Optimizing dose of tyrosine kinase inhibitors (TKIs) in the CML treatment maybe a new challenge to maintain effective and improving patients’ quality of life. We hypothesized that...

Full description

Bibliographic Details
Main Authors: Jie Luo, Xin Du, Jin Lou, Jianwei Wu, Liping Ma, Jixian Huang, Liangtuo Wang, Chuanqing Tu, Zelin Liu, Liya Chen, Yaxian Tan, Dongmei Luo, Hanyin Liang, Changxin Yin, Rui Cao, Xuan Zhou, Qifa Liu, Xiaoli Liu, Na Xu
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:eJHaem
Subjects:
chronic myeloid leukemia
de‐escalation TKI
treatment‐free remission
Online Access:https://doi.org/10.1002/jha2.550

Internet

https://doi.org/10.1002/jha2.550

Similar Items